GlassScriptPhysician profile
Peter Andrew Saitta
NPI 1750525341
$25,578.66
in general payments reported to CMS, 2019-2025
40 companies · $3,484 in 2025
The $3,484 reported for 2025 was more than what 87% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,186 · 2020: $1,239 · 2021: $2,387 · 2022: $3,238 · 2023: $3,604 · 2024: $3,440 · 2025: $3,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,138.68 |
| Education | $389.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $5,974.20 | 2019-2021 | |
| Abbvie INC. | $3,434.56 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $2,134.26 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $2,066.22 | 2019-2025 | Winlevi, Ilumya |
| Dermavant Sciences, INC. | $1,584.36 | 2022-2024 | Vtama |
| Galderma Laboratories, L.P. | $1,037.37 | 2019-2025 | Nemluvio, Aklief, Twyneo |
| Leo Pharma INC. | $1,036.88 | 2019-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $890.45 | 2023-2025 | Zoryve |
| Pfizer INC. | $759.79 | 2019-2025 | |
| Genzyme Corporation | $653.37 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $596.45 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $595.01 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $586.45 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Biofrontera INC. | $430.73 | 2021-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $418.03 | 2019-2022 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $417.10 | 2022-2025 | Sotyktu |
| Incyte Corporation | $366.29 | 2021-2025 | Opzelura |
| Medimetriks Pharmaceuticals, INC. | $350.00 | 2020 | |
| Ucb, INC. | $287.80 | 2022-2025 | Bimzelx, Cimzia |
| Encore Dermatology INC. | $239.56 | 2019-2020 | |
| Epi Health, LLC | $226.28 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $212.73 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $191.32 | 2020-2021 | |
| Amgen INC. | $170.27 | 2021-2025 | Otezla, Otezla |
| Almirall LLC | $155.60 | 2019-2025 | Seysara |
| Lnhc, INC | $144.45 | 2025 | Zelsuvmi |
| Celgene Corporation | $113.45 | 2019 | |
| Allergan, INC. | $81.69 | 2019-2021 | |
| Sandoz INC. | $79.96 | 2019-2021 | |
| Organon LLC | $69.57 | 2025 | Vtama |
| Botanix Sb INC | $50.09 | 2025 | Sofdra |
| Blueprint Medicines Corporation | $41.68 | 2023 | |
| Taro Pharmaceuticals USA, INC. | $37.26 | 2019 | |
| Merck Sharp & Dohme LLC | $29.70 | 2019 | |
| Journey Medical Corporation | $23.68 | 2019-2022 | |
| Promius Pharma LLC | $20.70 | 2019 | |
| Dermira, INC. | $19.94 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $19.12 | 2021 | |
| Sebela Pharmaceuticals INC. | $17.72 | 2022 | |
| Strata Skin Sciences, INC. | $14.57 | 2024 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Saitta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.